Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2394757 | 0.81 | CTSS (0.45) | CTSLCTSBCTSSPOLBSMN1; SMN2 | |
| SCHEMBL14705997 | 0.77 | P2RX7 (0.47) | CTSLCTSBCTSSPOLBSMN1; SMN2 | |
| SCHEMBL19920775 | 0.76 | CTSL (0.46) | CTSLCTSBCTSSPOLBSMN1; SMN2 | |
| SCHEMBL2389829 | 0.76 | CTSS (0.45) | CTSLCTSBCTSSPOLBSMN1; SMN2 | |
| SCHEMBL2395204 | 0.75 | CTSB (0.47) | CTSLCTSBCTSSPOLBSMN1; SMN2 | |
| SCHEMBL2391117 | 0.74 | CTSL (0.46) | CTSLCTSBCTSSPOLBSMN1; SMN2 | |
| SCHEMBL5097407 | 0.74 | MIF (0.49) | CTSLCTSBCTSSPOLBSMN1; SMN2 | |
| SCHEMBL16545238 | 0.72 | ALDH1A1 (0.45) | CTSLCTSBCTSSPOLBSMN1; SMN2 | |
| SCHEMBL22395151 | 0.72 | ATM (0.47) | CTSLCTSBCTSSPOLBSMN1; SMN2 | |
| SCHEMBL2391134 | 0.72 | CTSS (0.42) | CTSLCTSBCTSSPOLBCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12161625-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| EP-3922634-B1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230270719-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230270719-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230270719-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20210251957-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-08-19 | — | — | US | disclosed |
| US-10874640-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200061024-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061024-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | CTSL 1324/4885CTSB 2201/4885CTSS 3150/4885 |
| US-12161625-B2 | Substituted pyrrolizine compounds and uses thereof | HMBS, DHFR, HCCS | CTSL 1324/4885CTSB 2201/4885CTSS 3150/4885 |
| US-20230270719-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | CTSL 1324/4885CTSB 2201/4885CTSS 3150/4885 |
| US-10874640-B2 | Substituted pyrrolizine compounds and uses thereof | HMBS, DHFR, HCCS | CTSL 1324/4885CTSB 2201/4885CTSS 3150/4885 |
| US-20210251957-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | CTSL 1324/4885CTSB 2201/4885CTSS 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.